BXP Declares Regular Quarterly Dividend
Get Alerts BXP Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 4.3%
EPS Growth %: -30.4%
Join SI Premium – FREE
BOSTON--(BUSINESS WIRE)-- BXP, Inc. (NYSE: BXP), the largest publicly traded developer, owner, and manager of premier workplaces in the United States, announced today that its Board of Directors declared a regular quarterly cash dividend of $0.70 per share of common stock for the period April 1, 2026 to June 30, 2026, payable on July 31, 2026 to shareholders of record as of the close of business on June 30, 2026.
BXP, Inc. (NYSE: BXP) is the largest publicly traded developer, owner, and manager of premier workplaces in the United States, concentrated in six dynamic gateway markets - Boston, Los Angeles, New York, San Francisco, Seattle, and Washington, DC. BXP has delivered places that power progress for our clients and communities for more than 55 years. BXP is a fully integrated real estate company, organized as a real estate investment trust (REIT). As of March 31, 2026, including properties owned by unconsolidated joint ventures, BXP’s portfolio totaled 50.4 million square feet and 164 properties, including six properties under construction/redevelopment. For more information about BXP, please visit our website or follow us on LinkedIn or Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260617729128/en/
AT BXP
Mike LaBelle
Executive Vice President,
Chief Financial Officer
[email protected]
Helen Han
Vice President, Investor Relations
[email protected]
Source: BXP, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Torex Semiconductor Has Achieved "Zero" Current Consumption with Multi-Function Load Switch ICs XC8115/XC8116 Series
- Antengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE
- Innovent Biologics Announces First Patient Dosed in a Phase 3 Clinical Trial of IBI3003(GPRC5D/BCMA/CD3 Tri-specific Antibody) for the Treatment of Multiple Myeloma
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
DividendSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share